enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Target Price of $11.05 According to Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned an average rating of “Hold” from the fourteen ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $10.45.

ENGN has been the topic of several recent research reports. Weiss Ratings downgraded shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 30th. Citizens Jmp reissued a “market perform” rating on shares of enGene in a research report on Wednesday, September 9th. Citigroup downgraded shares of enGene from a “market perform” rating to a “hold” rating in a research report on Friday, October 16th. UBS Group restated an “outperform” rating on shares of enGene in a research note on Thursday. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of enGene in a report on Thursday.

enGene Trading Up 26.7%

NASDAQ ENGN opened at $2.28 on Friday. enGene has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $1.78 and a 200-day moving average price of $4.02.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). As a group, analysts predict that enGene will post -1.82 EPS for the current year.

enGene News Summary

These are some of the ENGN news items that stood out recently:

• Positive Sentiment: enGene reported updated results from Cohort 1 of its Phase 2 LEGEND trial of detalimogene in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. The company said it intends to initiate a Biologics License Application (BLA) submission by year-end, a key regulatory milestone. The provided report does not specify the updated efficacy figures. enGene trial and BLA announcement
• Positive Sentiment: Wells Fargo upgraded ENGN from Equal Weight to Overweight and raised its price target to $6 from $2. Piper Sandler also upgraded the stock to Overweight, with a $4 target. The upgrades signal improved analyst confidence following the trial update. Wells Fargo ratings Piper Sandler ratings
• Positive Sentiment: enGene appointed key executives ahead of anticipated regulatory and commercial milestones, potentially strengthening its ability to advance detalimogene toward approval and launch. Executive appointments

Institutional Trading of enGene

A number of institutional investors and hedge funds have recently bought and sold shares of ENGN. SR One Capital Management LP purchased a new stake in enGene during the second quarter valued at approximately $1,293,607. Eversept Partners LP boosted its stake in enGene by 12.0% during the first quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after buying an additional 54,708 shares during the period. Renaissance Technologies LLC increased its position in enGene by 651.1% during the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after acquiring an additional 135,318 shares during the last quarter. Siren L.L.C. increased its position in enGene by 57.5% during the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after acquiring an additional 1,916,895 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of enGene in the first quarter valued at $409,000. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.